Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 39, 2009 - Issue 2
Submit an article Journal homepage
2,160
Views
73
CrossRef citations to date
0
Altmetric
Research Article

Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design

E. S. PerloffBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USACorrespondence[email protected]
,
A. K. MasonBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
S. S. DehalBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
A. P. BlanchardBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
L. MorganBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
T. HoBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
A. DandeneauBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
R. M. CrockerBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
C. M. ChandlerBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
N. BoilyBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
,
C. L. CrespiBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
&
D. M. StresserBD Biosciences Discovery Labware, BD Gentest Contract Research Services, Woburn, MA, USA
 show all
Pages 99-112 | Received 22 Oct 2008, Accepted 20 Nov 2008, Published online: 01 Feb 2009

References

  • Akaike H. 1976. An information criterion (AIC). Math Sci 14:5–9.
  • Atkinson A, Kenny JR, Grime K. 2005. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637–1647.
  • Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. 2003. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–293.
  • Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. 2006. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro–in vivo extrapolation. Curr Drug Metab 7:315–334.
  • Kalgutkar AS, Obach RS, Maurer TS. 2007. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407–447.
  • Liebler DC, Guengerich FP. 2005. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 4:410–420.
  • Mayhew BS, Jones DR, Hall SD. 2000. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031–1037.
  • McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. 2006. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291–1300.
  • Obach RS, Walsky RL, Venkatakrishnan K. 2007. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35:246–255.
  • Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. 2006. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug Metab Dispos 34:191–197.
  • Segel IH. 1975. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state systems. New York, NY: Wiley.
  • Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR. 1994. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450–6455.
  • Silverman RB. 1996. Mechanism-based enzyme inactivators. In: Purich DL, ed. Contemporary enzyme kinetics and mechanism. Academic Press; New York, NY, USA. p. 291–334.
  • Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL. 2000. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440–1448.
  • Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL. 2004. Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105–112.
  • Stresser DM, Mason AK, Perloff ES, Ho T, Crespi CL, Dandeneau AA, Morgan L Dehal SS. 2009. Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine. Drug Metab Dispos (In Press).
  • US Food and Drug Administration (USFDA). 2001. Bioanalytical method validation. Guidance for industry. USFDA; Rockville, MD, USA.
  • US Food and Drug Administration (USFDA). 2006. Drug interaction studies – study design, data analysis, and implications for dosing and labeling. DRAFT guidance for industry. USFDA; Rockville, MD, USA.
  • Walsky RL, Obach RS. 2003. Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos 31:343.
  • Walsky RL, Obach RS. 2004. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660.
  • Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR. 2005. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413–418.
  • Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. 2005. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334–340.
  • Yeo KR, Yeo WW. 2001. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51:461–470.
  • Zhou SF, Xue CC, Yu XQ, Li C, Wang G. 2007. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.